Sanofi MS Drug Meets Goal of Reducing Disability in Late-Stage Trial
By David Sachs
Sanofi's experimental multiple sclerosis drug has shown promising results in a late-stage trial, delaying disability progression in patients and paving the way for discussions with regulators about potentially bringing the drug to market.
The French pharmaceutical company said tolebrutinib, a treatment taken orally for people with non-relapsing secondary progressive multiple sclerosis, met its primary goal of improvement versus a placebo.
However, earlier studies failed to show significant improvement in reducing relapse rates versus Aubagio, another MS drug on the market, Sanofi said.
The company will present results at a medical meeting on Sept. 20.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
September 02, 2024 01:39 ET (05:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States